Business profile & competitive position
The Cooper Companies, Inc. (COO) sits in the Healthcare sector, specifically the Medical - Instruments & Supplies industry. It operates two segments rather than a single product line. CooperVision develops, manufactures and markets daily, two-week and monthly contact lenses, including silicone hydrogel lenses, orthokeratology and scleral lenses, plus the MiSight 1 day myopia-management lens. CooperSurgical offers more than 600 products and services concentrated on fertility and women’s health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood/tissue storage, IVF support, donor gametes, cryopreservation and genomic services. The company’s products are sold in over 130 countries and reach more than fifty million lives each year.
What do the returns say about its competitive moat? The 13.5% net margin is consistent with a profitable recurring-consumable medical-device business, but it is not the margin profile usually associated with deeply entrenched, asset-light intellectual property franchises. ROE is just 6.9%, well below the low-double-digit level many investors use as a rough benchmark for a strong economic moat. That combination suggests value is created through breadth, regulatory differentiation and global distribution rather than through high balance-sheet efficiency. The most concrete evidence of regulatory differentiation is that MiSight 1 day is the only contact lens approved by the FDA, Chinese NMPA and Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children. That kind of multi-jurisdictional clearance is difficult to replicate, even if the modest ROE figure reflects the capital intensity required to maintain global scale.
Financial posture
At the snapshot date, COO carried an $11.3 billion market capitalization and traded at a P/E ratio of 20.3. That multiple sits in a middle-of-the-road range for a profitable healthcare-device company. The 13.5% net margin and 6.9% ROE are neither distressed nor exceptional. Beta is 0.82, meaning the stock has historically moved about 18% less than the overall market, a profile typical of defensive Healthcare names.
The current price was $59.55, with RSI at 52.5 and the 50-day EMA at $60.57. Those markers place the shares near, but slightly under, their short-term moving average, neither heavily overbought nor oversold. Because the supplied snapshot does not include a leverage or debt figure, any capital-structure conclusion would be speculative; the posture assessment is therefore confined to the valuation and profitability metrics actually provided.
Strategic priorities & outlook
The company’s most recent 10-K outlines a near-term operational agenda built around three levers. Within CooperVision, management wants broader worldwide market penetration of recently introduced products, deeper presence in existing and emerging markets, and increased investment in distribution and packaging to support growth and quality of service. It is also investing to develop the myopia-management market, primarily by educating eye-care practitioners, patients and their families.
On the CooperSurgical side, the plan is to continue investing, including through strategic transactions, to expand an integrated solutions model across fertility and women’s health. Those efforts are supported by an R&D base of approximately 500 employees across both segments. Because the business is weighted toward recurring consumables, progress on these priorities will likely show up as incremental volume and market-share shifts rather than as dramatic one-time product cycles.
Macro & geopolitical exposure
As a Medical - Instruments & Supplies name, COO’s macro exposures follow the healthcare-device script. Regulatory oversight and reimbursement are central: contact lenses are regulated medical devices, and fertility and women’s health products face oversight from the FDA and comparable foreign agencies. Policy shifts around insurance coverage for IVF, contraception or myopia treatment can affect demand, while reimbursement-rate pressure can compress pricing power.
Currency exposure is also meaningful. With products sold in over 130 countries, dollar strength or weakness can either flatter or compress reported results. The industry depends on global supply chains for specialized polymers, packaging materials and sterilization logistics, so input costs and transport conditions matter. Broader trade-policy changes affecting medical-device components can ripple through margins. For this company in particular, the multi-regulatory MiSight approvals highlight both the opportunity of global regulatory reach and the ongoing burden of maintaining compliance across jurisdictions.
Recent developments
Heading into November 2026, the stock has faced elevated headline risk around securities-investigation activity. On October 30, 2026, three separate releases highlighted the issue:
- newsfilecorp.com reported that ROSEN, a leading investor counsel, encouraged The Cooper Companies investors to inquire about a securities class-action investigation.
- prnewswire.com issued a report scrutinizing COO over U.S. channel inventory reductions and describing those concerns as driving the stock sharply lower.
- globenewswire.com reported that Glancy Prongay & Wolke and Rotter LLP continued investigating possible securities fraud after a 14.67% share-price drop.
A day earlier, on October 29, 2026, globenewswire.com carried another release from The Rosen Law Firm inviting investors who had suffered losses to contact the firm about their rights. These items are plaintiff-side investigations, not findings of liability, but they have added to the recent volatility narrative.
Earnings behavior & post-earnings drift
COO has beaten consensus earnings in all of the last eight reported quarters, an 8/8 beat rate, with an average earnings surprise of 4.2%. Despite that consistency, the average five-day price move after those reports is -2.34%, classified as a downward drift. That disconnect is the central earnings pattern in the data: beating estimates has not reliably produced a positive post-earnings drift.
The last four quarters illustrate the split:
- September 9, 2026: EPS $1.15 vs. estimate $1.12, a 2.7% positive surprise — but the stock fell 14.67% the next day and 13.97% over the following five days.
- June 4, 2026: EPS $1.21 vs. estimate $1.10, a 10.0% positive surprise, with the stock rising 8.58% the next day and 8.85% over five days.
- March 5, 2026: EPS $1.10 vs. estimate $1.03, a 6.8% positive surprise, yet the stock dropped 4.55% the next day and 10.82% over five days.
- December 4, 2025: EPS $1.15 vs. estimate $1.11, a 3.6% positive surprise, producing a 5.67% next-day gain and a 6.59% five-day gain.
Four consecutive beats, with only two of the four followed by a positive five-day move. The most recent report, September 9, 2026, was especially severe despite the beat. The next scheduled report is December 3, 2026, after the close, with a consensus EPS estimate of $1.07. The practical takeaway is that the headline beat is only part of the story; guidance, channel commentary and the market’s real expectation all appear to drive the after-hours and post-earnings price action.
Frequently Asked Questions
Why has COO stock sometimes fallen after beating earnings?
Even though COO has an 8/8 beat rate with an average surprise of 4.2%, the average five-day post-earnings drift is -2.34%. Recent examples show guidance, channel inventory commentary and forward expectations can outweigh the headline beat, as seen on September 9, 2026, when a 2.7% beat coincided with a 14.67% single-day drop.
What are CooperVision and CooperSurgical focused on?
Per the company’s 10-K, CooperVision is focused on worldwide market penetration of newer products, distribution and packaging capacity, and growing the myopia-management market through education. CooperSurgical plans continued investment, including strategic transactions, to expand its integrated fertility and women’s health model.
What macro factors matter most for a Medical - Instruments & Supplies company like COO?
Regulatory approvals and reimbursement policy, currency translation across 130+ countries, and global supply-chain costs for polymers, packaging and sterilization logistics are the industry-level exposures. Reproductive-health policy can also influence the CooperSurgical segment.
For a deeper dive into the bull and bear cases, institutional price targets and consensus model revisions, take a look at the full institutional verdict on COO.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-09-09 | $1.15 | $1.12 | +2.7% | -14.67% | -13.97% |
| 2026-06-04 | $1.21 | $1.1 | +10% | +8.58% | +8.85% |
| 2026-03-05 | $1.1 | $1.03 | +6.8% | -4.55% | -10.82% |
| 2025-12-04 | $1.15 | $1.11 | +3.6% | +5.67% | +6.59% |
| 2025-08-27 | $1.1 | $1.07 | +2.8% | - | - |
| 2025-05-29 | $0.96 | $0.928 | +3.4% | - | - |
Previous COO editions
Get the institutional verdict on COO
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the COO verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.